The purpose of the study is to demonstrate that the N‑AVD regimen is not worse than the BrECADD regimen in achieving a complete metabolic response, which is evaluated using PET/CT imaging about six to eight weeks after the chemotherapy is finished.

Participants receive the assigned drugs by infusion or injection every three weeks for a series of treatment cycles. After the final cycle, a PET/CT scan checks whether the cancer has disappeared. Follow‑up visits continue for several years to monitor overall survival, disease‑free time, quality of life, and any side effects, with occasional blood tests to look for disease markers and hormone recovery.

The purpose of this study is to estimate how well the treatment with pembrolizumab followed by radiotherapy works in people with this type of lymphoma. Pembrolizumab is an anti-PD-1 antibody, which means it works by helping the body’s own immune system recognize and fight the cancer cells more effectively. The medicine is given through an infusion, which means it is slowly delivered into a vein over a period of time. After completing the pembrolizumab treatment, patients will receive radiotherapy to the areas where the cancer was found.

During the study, patients will receive pembrolizumab at a dose of up to 200 milligrams per treatment session, with a maximum total dose of 1200 milligrams over a treatment period of up to six weeks. The study will check how well the treatment works by measuring whether the disease comes back or gets worse within one year after treatment starts. Doctors will also look at the status of the disease after the pembrolizumab treatment and again after the radiotherapy is completed. Additional measurements will include how many patients are alive without their disease getting worse at two years, how many patients are alive at one and two years, any unwanted effects that occur during and after treatment, and how patients feel during and after their treatment through questionnaires.

The treatment plan involves multiple medications administered through infusion into a vein or taken orally. These include brentuximab vedotin, dacarbazine, etoposide, doxorubicin, cyclophosphamide, and dexamethasone. The treatment regimen consists of one dose of pembrolizumab followed by four to six cycles of combination therapy. Some patients may also receive radiation therapy as part of their standard care.

The purpose of this study is to determine how well this new treatment combination works in controlling the disease. Doctors will monitor patients’ response to treatment and track their health status for at least one year after starting the therapy. The treatment approach being tested aims to improve outcomes for patients with advanced Hodgkin Lymphoma by combining targeted therapy with traditional chemotherapy medications.

The purpose of the study is to evaluate the safety and potential side effects of the HSP-CAR30 treatment. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor participants closely for any side effects or reactions to the treatment. This will help researchers understand how the treatment works and how it affects the body.

In addition to HSP-CAR30, the study involves other medications that may be used in combination with the main treatment. These include Levact (bendamustine hydrochloride), Fludarabina Accord (fludarabine phosphate), Genoxal (cyclophosphamide monohydrate), and RoActemra (tocilizumab). These medications are also given through intravenous infusion and are used to help manage the cancer or support the immune system. The study will continue until the end of 2025, with participants being monitored throughout the process to gather important data on the treatment’s effectiveness and safety.

The study will also investigate the use of a medication called Nivolumab for patients who are at a higher risk of the disease progressing. Nivolumab is given through an infusion, which means it is administered directly into the bloodstream. The trial will look at how well this medication works in combination with chemotherapy for those who do not respond as well to the initial treatment. The goal is to see if this combination can help prevent the disease from coming back or getting worse over a period of three years.

Participants in the study will undergo regular monitoring to track their progress and response to the treatment. The study will assess the safety and effectiveness of the treatment plan, including the use of Nivolumab, to determine if it can improve outcomes for patients with early-stage Hodgkin Lymphoma. The trial will continue until 2026, with the aim of providing valuable insights into the best treatment strategies for this type of cancer.

The purpose of the study is to understand how the body processes Pembrolizumab when given as a subcutaneous injection and to evaluate its effectiveness and safety in treating these cancers. Participants will receive the treatment in cycles, and researchers will monitor how the drug is absorbed and how well it works in reducing cancer symptoms. The study will also look at the overall response of the cancer to the treatment, as well as any side effects that may occur.

Throughout the study, participants will undergo regular assessments to track their response to the treatment and any changes in their condition. The study aims to provide valuable information on the potential benefits and risks of using Pembrolizumab in this new form of administration for patients with these specific types of lymphoma.

The treatment involves receiving either Brentuximab Vedotin combined with ESHAP or ESHAP alone for three treatment cycles. Brentuximab Vedotin is given through an intravenous infusion, which means it is delivered directly into a vein. The maximum daily dose is 180 milligrams, and the treatment period can last up to 58 weeks. After the initial treatment cycles, patients who show complete remission will receive additional Brentuximab Vedotin treatment instead of undergoing a stem cell transplant.

During the study, doctors will use special imaging scans called PET-CT to check how well the treatment is working. The study will monitor patients for up to three years to track their progress and any long-term effects of the treatment. This includes checking for signs of disease progression, overall health status, and quality of life.

The purpose of the study is to find the best dose of atezolizumab when used with the BEGEV regimen and to see how well this combination works before patients undergo a procedure called autologous stem-cell transplantation. This procedure involves using a patient’s own stem cells to help restore their bone marrow after intensive treatment. The study is divided into two phases. In the first phase, researchers will determine the safest and most effective dose of atezolizumab. In the second phase, they will assess how well the treatment works in reducing the cancer before the stem-cell transplantation.

Participants in the study will receive the treatment over several cycles, with regular assessments to monitor their response to the therapy. The study aims to provide valuable information on the effectiveness and safety of this treatment combination for patients with relapsed or refractory Hodgkin’s lymphoma. The results will help guide future treatment options for this condition.

The purpose of the study is to assess the safety and initial effectiveness of AZD7789 in patients with this type of lymphoma. The study is divided into two parts. In the first part, different doses of AZD7789 will be tested to find the safest and most effective dose. In the second part, the study will continue to evaluate the safety and how well the treatment works in a larger group of patients. Some patients in this part of the study will have had previous treatments targeting PD-1 or PD-L1, while others will not have had these treatments before.

Throughout the study, patients will receive AZD7789 through an infusion, which is a way of delivering the medicine directly into the bloodstream. The study will monitor patients for any side effects and changes in their health. The goal is to determine if AZD7789 can help control the cancer and improve the patients’ condition. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the new treatment. The study is expected to continue until 2025.

The study aims to find out if using a medication called Levothyroxine can help reduce the risk of developing hypothyroidism after radiation therapy. Levothyroxine is a medication that helps to replace or supplement the hormones that the thyroid gland usually produces. In this study, some patients will receive Levothyroxine during their radiation treatment, while others will not, to see if it makes a difference in preventing hypothyroidism.

Participants in the study will be monitored for three years after their radiation therapy to check for signs of hypothyroidism. The goal is to determine if Levothyroxine can help protect the thyroid gland during radiation treatment and improve the long-term health of patients with these types of cancer. This research is important for finding better ways to manage the side effects of cancer treatments and improve the quality of life for patients.

The purpose of the study is to assess how well the treatment works in achieving a complete response, which means the disappearance of all signs of cancer in the body, in patients who have not been treated before. Participants in the study will receive the treatment through intravenous infusion, which means the medication is given directly into a vein. The study will be conducted over several parts, and each part will have a specific focus on different aspects of the treatment and its effects on the disease.

Throughout the study, participants will be monitored for any side effects or changes in their condition. The study aims to gather information on the safety and effectiveness of the treatment, as well as to understand how the disease responds to the combination of medications. The trial is expected to continue until 2027, providing valuable insights into the treatment of Classical Hodgkin Lymphoma.

The purpose of the study is to evaluate how well tislelizumab works as a first-line treatment for these patients. Tislelizumab is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream. The study will monitor the overall response rate, which includes both complete and partial responses to the treatment. Participants will receive the treatment over a period of up to 24 months, and their health will be closely monitored throughout the study.

In addition to assessing the response to the treatment, the study will also look at other important factors such as how long the response lasts, the time patients remain free from disease progression, overall survival rates, and any side effects that may occur during and after the treatment. This information will help determine the potential benefits and risks of using tislelizumab for treating Hodgkin lymphoma in patients who cannot undergo standard chemotherapy.

The purpose of the study is to evaluate how well the combination of pembrolizumab and chemotherapy works in treating patients with slow early response to initial treatment. Participants will receive the study treatment over a period of time, and their response to the treatment will be monitored. The study will also compare the effectiveness of different chemotherapy combinations, such as AVD (doxorubicin, vinblastine, and dacarbazine) and COPDAC-28 (cyclophosphamide, vincristine, prednisone, and dacarbazine), in achieving a negative result on a PET scan, which is a type of imaging test that helps doctors see how the cancer is responding to treatment.

Throughout the study, researchers will track various outcomes, including the rate of response to treatment, survival rates, and any side effects experienced by participants. The study aims to provide valuable information on the best treatment options for children and young adults with Classical Hodgkin Lymphoma who do not respond well to initial chemotherapy. The trial is expected to continue until 2028, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment.

The purpose of the study is to evaluate and compare the effectiveness of these two treatments in managing Hodgkin lymphoma. Participants in the study will receive either Pembrolizumab or Brentuximab Vedotin, and their progress will be monitored over a period of time. The study will look at how long patients live without the disease getting worse, known as progression-free survival, and overall survival, which is the length of time patients live after starting the treatment. Additionally, the study will assess the objective response rate, which measures how well the cancer responds to the treatment.

Throughout the study, participants will undergo regular check-ups and imaging tests to track the progress of their treatment. These tests help doctors understand how the cancer is responding to the medication. The study aims to provide valuable information that could improve treatment options for people with relapsed or refractory Hodgkin lymphoma.

The purpose of the study is to evaluate how well this combination of treatments works in preventing the cancer from getting worse or coming back over a period of two years. Patients will receive the combination of Tislelizumab, Gemcitabine, and Cisplatin initially, followed by additional doses of Tislelizumab if they achieve a complete remission, meaning no signs of cancer are detected. The study will monitor patients’ health and response to the treatment over time to gather information on the effectiveness and safety of these medications.

Participants in the study will receive the treatments through intravenous infusions, which means the medications are given directly into a vein. The study will last for several months, with regular check-ups and assessments to track the progress of the treatment. The goal is to find out if this treatment approach can help patients with relapsed or refractory Hodgkin lymphoma live longer without their disease progressing.

The purpose of this research is to determine if the modified chemotherapy regimen (A2VD) can improve how long patients remain free from disease progression compared to the standard treatment. Patients will receive either ABVD or A2VD chemotherapy, and depending on their response as shown on PET scans after two treatment cycles, they may continue with the same treatment or receive additional radiation therapy.

This study is designed for patients with early-stage Hodgkin lymphoma who have not received previous treatment for their disease. The study will monitor patients for treatment effectiveness, side effects, and long-term outcomes including the development of second cancers and heart disease.

The purpose of the study is to see how well MK-4280A works in treating patients with this type of lymphoma compared to other chemotherapy options. Participants in the study will receive either the new treatment or one of the standard chemotherapy treatments. The study will monitor how the disease responds to the treatment and how long the response lasts. It will also track the overall survival of participants and any side effects they may experience during the study.

This trial is designed to help researchers understand if MK-4280A can provide a better treatment option for patients with Classical Hodgkin Lymphoma that has not responded to other therapies. The study will take place over several months, and participants will be closely monitored by healthcare professionals throughout the process to ensure their safety and to gather important information about the treatment’s effectiveness.

The purpose of the study is to understand how well these medications work together and how the body handles them. Participants will receive the treatment and be monitored for any side effects and how their cancer responds. The study is divided into two parts: the first part focuses on children under 18 years old to determine the safest dose, and the second part includes young adults up to 30 years old to assess how well the treatment works based on the findings from the first part.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the progress of their treatment. The goal is to find a new, effective treatment option for those whose cancer has returned or not responded to standard therapies. This study is an important step in exploring new ways to help young patients with these challenging conditions.

The purpose of this study is to evaluate how well the combination of Pembrolizumab and chemotherapy works in treating patients who have been newly diagnosed with Classical Hodgkin Lymphoma. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants’ response to the treatment over a period of time, assessing how effectively the cancer is being controlled or reduced.

Throughout the study, participants will be closely observed to track their progress and any side effects they may experience. The goal is to determine the complete response rate, which refers to the disappearance of all signs of cancer in response to the treatment. This information will help researchers understand the potential benefits and risks of using Pembrolizumab in combination with chemotherapy for treating Classical Hodgkin Lymphoma.

The purpose of the study is to see if adjusting the treatment based on early results from a special type of scan called FDG-PET/CT can improve the effectiveness of the treatment while reducing side effects. Participants will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will follow a specific plan where the treatment is adjusted based on the early scan results. This approach aims to find the best way to treat the disease with the least amount of side effects.

Throughout the study, the main focus will be on how long patients can live without the disease getting worse, which is known as progression-free survival. Other aspects being looked at include the overall survival of patients, the safety and tolerability of the treatment, and the response to the treatment according to specific criteria. The study will also involve taking additional blood samples and using tissue samples to help understand the treatment’s effects better.

The study will be conducted in two parts. In the first part, participants with advanced solid tumors will receive the combination of cobolimab and dostarlimab to assess safety and determine the appropriate dosage. In the second part, the study will focus on specific types of cancer, including melanoma and Hodgkin lymphoma, to evaluate the effectiveness of the treatment. Participants will receive the medications through an intravenous infusion, which means the medicine is given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The trial will help researchers gather important information about the potential benefits and risks of using cobolimab and dostarlimab together in treating these challenging conditions. The study is expected to continue until 2030, providing valuable insights into new treatment options for young patients with difficult-to-treat tumors.

Participants in the study will receive either the GnRHa treatment or a placebo, which is a substance with no active medication. The GnRHa treatment being studied is called Pamorelin, which is given as an injection. There are two different doses of Pamorelin being used in the study: 3.75 mg and 11.25 mg. The study will follow participants for several years to monitor their ovarian reserve and other health factors. This includes measuring levels of a hormone called Anti-Müllerian Hormone (AMH), which helps indicate the number of eggs left in the ovaries, at various points after the end of chemotherapy.

Throughout the study, participants will have regular check-ups to assess their ovarian reserve and overall health. This will involve tests like ultrasounds and blood tests to measure hormone levels. The study aims to provide valuable information on how GnRHa might help preserve fertility in young women and teenagers undergoing cancer treatment. By understanding the effects of this treatment, researchers hope to improve future care for patients facing similar challenges.